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Emerging Governance of Mitochondrial Replacement Therapy: Assessing Coherence Between 
Scientific Evidence and Policy Outcomes  
 
I. Introduction 
 
In the fall of 2016, media headlines reported news of the first baby born as a result of 
what has been called “three parent IVF” or mitochondrial replacement therapy (“MRT”).1  The 
initial report indicated Dr. John Zhang, of the New York New Hope Fertility Center worked with 
a couple from Jordan and traveled to Mexico to perform a procedure called maternal spindle 
transfer.2  New Scientist first described the “great news” of the first known birth of the child born 
to the Jordanian couple at risk for mitochondrial disease.3  Reports asserted the infant “appeared 
to be healthy,” but did not provide substantive evaluation of the infant.4   
Science Magazine characterized this transnational arrangement as a means for desperate 
parents who wish to bear a genetically related child free from fatal genetic disease.5  Media 
described MRT as a technique that allows parents with rare genetic mutations “to have healthy 
babies” because it constitutes a “treatment, or even a cure” and praised the courageous Dr. Zhang 
as a pioneer whose work “should fast-forward progress” against regulatory barriers in the United 
                                                          
1 Jessica Hamzelou, World’s First Baby Born With New “3 Parent” Technique, NEW SCIENTIST 
(Sept. 27, 2016), https://www.newscientist.com/article/2107219-exclusive-worlds-first-baby-
born-with-new-3-parent-technique/; Jennifer Couzin-Frankel, Unanswered Questions Surround 
Baby Born to Three Parent, SCIENCE (Sept. 27, 2016), 
http://www.sciencemag.org/news/2016/09/unanswered-questions-surround-baby-born-three-
parents. 
2 Id.  
3 Id. 
4 Couzin-Frankel, supra note 1; see also Sara Reardon, Reports of “Three-Parent Babies” 
Multiply, NATURE NEWS (Oct. 19, 2016), http://www.nature.com/news/reports-of-three-parent-
babies-multiply-1.20849. 
5 Id. 
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States. 6  One stem cell biologist asserted regulatory barriers have “[put] novel treatments on the 
long bench, and therefore it had to be done that way.” 7  The British Broadcasting Corporation 
(BBC) praised Dr. Zhang as acting ethically on his mission to “save lives” and assist families in 
need of treatment.8   
 Weeks later, more reports surfaced that Dr. Valery Zukin, a physician in Kiev, Ukraine 
used MRT to “treat” general infertility for two patients in his clinic.9 Similar to descriptions of 
Dr. Zhang’s actions, Nature reported during the pregnancies that Dr. Zukin’s technique “seems 
to have fixed the problem” on the premise that the pregnancy continued to progress.10  Months 
later following the birth of the first infant, the media repeated the claim of good news, asserting 
that after fifteen years of infertility, the patient in Dr. Zukin’s clinic finally gave birth to a 
“healthy baby” that is genetically her own.11 
 MRT described in this article currently refers to two procedures.   In the first procedure, 
maternal spindle transfer (“MST:), the nucleus in the mother’s oocyte is removed and transferred 
                                                          
6 Id.; Alexandra Ossola, FDA Expected to Approve Technique to Create “The Three-Parent 
Babies,” POPULAR SCIENCE (Feb. 3, 2016), http://www.popsci.com/fda-approves-technique-to-
create-three-parent-babies. 
7 Reardon, supra note 4. 
8 Michelle Roberts, First “Three Person Baby” Born Using New Method, BBC NEWS (Sept. 27, 
2016), http://www.bbc.com/news/health-37485263. 
9 Andy Coghlan, “3-Parent” Baby Method Already Used for Infertility, NEW SCIENTIST (Oct. 10, 
2016), https://www.newscientist.com/article/2108549-exclusive-3-parent-baby-method-already-
used-for-infertility/. 
10 Reardon, supra note 4; see also Andy Coghlan, First Baby Born Using 3-Parent Technique to 
Treat Infertility, NEW SCIENTIST (Jan. 18, 2017), https://www.newscientist.com/article/2118334-
first-baby-born-using-3-parent-technique-to-treat-infertility/. 
11 59th MEETING OF THE CELLULAR, TISSUE, AND GENE THERAPIES ADVISORY COMMITTEE, FDA 
(Feb. 25, 2014), 
https://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/BloodVacci
nesandOtherBiologics/CellularTissueandGeneTherapiesAdvisoryCommittee/UCM390945.pdf at 
19-21 [hereinafter “FDA Meeting”]. 
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into a donor oocyte whereby the donor oocyte is subsequently fertilized.12  The second method is 
referred to as pronuclear transfer (“PNT”), where both the mother’s oocyte is fertilized and the 
donor oocyte is fertilized with sperm in vitro, which creates two zygotes.  The nucleus from the 
fertilized donor zygote is removed and is then replaced with the nucleus from the mother’s stage 
matched zygote.13  These experimental techniques that promise to “swap in healthy 
mitochondria” have come under additional scrutiny because MRT entails nuclear genome 
transfer, which constitutes a modification of the germline that breaches the historical bright line 
of impermissible interventions on human embryos used for implantation.14  
Despite a number of international agreements and criminal prohibitions against germline 
modification in other countries abroad, there is no such legal prohibition in the United States.15  
Last year in the United Kingdom, the Human Fertilisation and Embryology Authority announced 
it would begin reviewing license applications from fertility clinics that wished to offer MRT to 
patients as a means to avoid mitochondrial disease.  In the United States, the FDA has discussed 
scientific considerations and the National Academy of Sciences, Engineering, and Medicine 
                                                          
12 Id.  
13 Rosa Castro, Mitochondrial Replacement Therapy: the U.K. and US Regulatory Landscapes, 3 
J. OF L. & THE BIOSCIENCES 726, 728 (2016); FDA Briefing Document: Oocyte Modification in 
Assisted Reproduction for the Prevention of Transmission of Mitochondrial Disease or the 
Treatment of Infertility, CELLULAR, TISSUE, & GENE THERAPIES ADVISORY COMM., FDA (Feb. 
25-26, 2014) [hereinafter “FDA Brief”]; Mitochondrial Replacement Techniques: Ethical, 
Social, and Policy Considerations, NAT’L ACADS. OF SCI. ENG’G & MED. at 20-21 (2016) 
[hereinafter “NAS Report”]. 
14 FDA Should Preserve International Consensus Against Human Germline Modifications, 
Center for Genetics and Society (Feb. 19, 2014), 
http://www.geneticsandsociety.org/article.php?id=7528. 
15 Tetsuya Ishii, Potential Impact of Human Mitochondrial Replacement on Global Policy 
Regarding Germline Gene Modification, 29 REPROD. BIOMEDICINE ONLINE 150, 152-53 (2014); 
Motoko Araki & Tetsuya Ishii, International Regulatory Landscape and Integration of 
Corrective Genome Editing Into In Vitro Fertilization, 12 REPROD. BIOLOGY & ENDOCRINOLOGY 
9 (2014); Rosario Isasi et al., Editing Policy to Fit the Genome? 351 SCIENCE 337 (2016). 
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concluded it is ethically permissible to conduct clinical investigations subject to a set of 
conditions.  Notably, FDA discussions have not only considered MRT as a potential 
investigational method for treating mtDNA disease, but also as an option for treating infertility.   
Drawing upon the process in the U.K., this article examines the regulatory framework 
developed in the U.K., contrasts this system with nations that prohibit or criminalize germline 
interventions, and describes the regulatory and policymaking discussions that have occurred in 
the United States.  In response to the recent amendments to the law in the U.K. and current 
reproductive tourism for MRT, this article will describe efforts at public engagement during the 
policymaking process and the ethical divide pertaining to germline modifications.  This article 
will synthesize the currently known scientific considerations pertaining to safety, efficacy, and 
risk related to mitochondrial biology, oocyte modification, and oocyte donation.  Finally, the 
article will evaluate the medical rationale provided by proponents that such technology is both 
necessary and beneficial and consider the impact of commercial interests on the development of 
MRT.  
II. Primer on Mitochondrial Biology 
Mitochondria are organelles found in almost every cell in the human body and serve a 
number of functions including energy production, controlling metabolic processes, and 
programming cell growth and apoptosis.16  Far from being mere “batteries” of the cell, scientists 
now recognize extensive interaction between mitochondrial DNA (“mtDNA”) and nuclear DNA 
                                                          
16 FDA Brief, supra note 13, at 5; Anne Claiborne et al., Finding an Ethical Path Forward for 
Mitochondrial Replacement, 351 SCIENCE 668 (2016); Kimberly Dunham-Snary & Scott 
Ballinger, Mitochondrial-Nuclear DNA Mismatch Matters, 349 SCIENCE 1449 (2015); Eli Adashi 
& I. Glenn Cohen, Going Germline: Mitochondrial Replacement as a Guide to Genome Editing, 
164 CELL 832 (2016). 
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(“nDNA”) that directly impacts gene expression and cell function.17  Mitochondria are 
maternally inherited, and pathogenic mutations in mtDNA can present as a number of serious 
and potentially fatal diseases.18  Mitochondrial dysfunction may result in a variety of disorders 
affecting tissues with a high metabolic demand, such as the brain, heart, muscle, and central 
nervous system.19 
Although many individuals in the population may carry mtDNA mutations, these 
mutations will not result in dysfunction unless the percent of mutant mitochondria reaches a 
particular threshold.20  Currently, in the process of both MST and PNT a small percent of 
cytoplasm is transferred along with the nucleus during the nuclear genome transfer from the 
mother’s oocyte or zygote into the donor’s.21  Although the rate of carryover of mtDNA has been 
reportedly low, scientists believe the percent of the mother’s mutated mtDNA could increase.22   
Scientists refer to the percent mix of mutant mitochondria as degree of heteroplasmy.23  When 
cells divide during embryogenesis, gametogenesis, and during the course of normal 
development, the levels of mutant mitochondria may increase in the dividing cells, which can 
lead to differential replication and segregation toward a higher degree of heteroplasmy, even in 
                                                          
17 FDA Brief, supra note 13, at 5; FDA Meeting, supra note 11, at 18, 24-31; Klaus Reinhardt et 
al., Mitochondrial Replacement, Evolution, and the Clinic, 341 SCIENCE 1345, 1346. 
(2013)(discussing the impact of mtDNA on nDNA expression and cross-talk between mtDNA 
and nDNA).  
18 FDA Brief, supra note 13, at 8. 
19 Paula Amato et al., Three Parent In Vitro Fertilization: Gene Replacement for the Prevention 
of Inherited Mitochondrial Disease, 101 FERTILITY & STERILITY 31 (2014). 
20 FDA Meeting, supra note 11, at 34-41 (discussing heteroplasmy and disease threshold) and at 
66 (hypothesis that we all have naturally occurring heteroplasmy). 
21 FDA Meeting, supra note 11, at 21, 123, 168; FDA Brief, supra note 13, at 14-15, 20; NAS 
Report, supra note 13, at 47. 
22 FDA Meeting, supra note 11, at 34-41 
23 Id. 
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varying levels through different tissues in the body.24  Scientists describe a phenomenon referred 
to as maternal bottleneck, defined as when levels of heteroplasmy increase from one generation 
to the next.25  For example, a mother with a low level of heteroplasmy who may not display signs 
of mitochondrial dysfunction and appears healthy could give birth to a child with a high level of 
heteroplasmy that would reach the threshold and present as mitochondrial disease.26 
Mitochondrial disease can arise from either mtDNA mutations or nDNA mutations, 
though inherited mtDNA mutations are rare.  According to evidence presented at the Cellular, 
Tissue, and Gene Therapies Advisory Committee meeting in 2014, maternal transmission of 
mtDNA disease is rare and only occurs in 1/10,000 individuals.27  This distinction provides 
crucial perspective, because failing to distinguish between maternally inherited mtDNA disease 
and nDNA mitochondrial disease can skew public perceptions of statistical occurrence in a 
misleading manner.  During the public engagement process in the U.K., Human Fertilisation  and 
Embryology Authority characterized the frequency of mitochondrial mutations as affecting 1/200 
individuals, and one headline proclaimed nearly 2500 women could benefit from MRT in the 
U.K.28  Yet these figures omitted discerning between mtDNA disease and mitochondrial disease 
resulting from nDNA mutations.29  Most cases of mitochondrial disease arise from de novo 
                                                          
24 Id.  
25 Id. at 34-35. 
26 Id. at 132-35. 
27 Id. at 64.  
28 Human Genetic Engineering on the Doorstep, HUMAN GENETICS ALERT (Nov. 2012) at 4, 
http://www.hgalert.org/Mitochondria%20briefing.pdf; Nearly 2,500 Women Could Benefit from 
Mitochondrial Donation in the U.K., SCIENCE DAILY (Jan. 29, 2015), 
https://www.sciencedaily.com/releases/2015/01/150129094353.htm. 
29 See Francoise Baylis, The Ethics of Creating Children With Three Genetic Parents, 26 
REPROD. BIOMEDICINE ONLINE 531 (2013). 
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mutations (new mutations in mtDNA not present in the maternal line) and mutations in nDNA.30 
Approximately 80% of mitochondrial disease arises from nDNA mutations, for which MRT does 
not address.31  When subtracting the incidence of nDNA disease, the final potential pool of cases 
where MRT may apply falls to ten persons a year for the population cited in the discussion 
pertaining to the U.K.32   
There is currently no FDA approved treatment for mitochondrial disease.33  Literature has 
discussed potential alternative methods designed to avoid mitochondrial disease: adoption, pre-
implantation genetic diagnosis (“PGD”), and use of an oocyte donor.34  Some scholars have 
rejected adoption and use of an oocyte donor because it overlooks parental desire to bear a 
genetically related child.35 PGD may reduce, but not eliminate the chance for a child without 
mitochondrial disease based on uncertainty of whether the subsequent cellular division would 
result in genetic drift, defined as increasing rates of mutant DNA and heteroplasmy that reaches 
the threshold for disease.36   
 
                                                          
30 FDA Meeting, supra note 11, at 58-64; see also NAS Report, supra note 13, at 27 (discussing 
mtDNA disease generally relating to later onset milder conditions and nDNA disease 
constituting earlier onset and more severe expressivity). 
31 Third Scientific Review of the Safety and Efficacy of Methods to Avoid Mitochondrial Disease 
Through Assisted Conception: 2014 Update, HUM. FERTILISATION & EMBRYOLOGY AUTH. at 12 
(June 2014) [hereinafter “HFEA Scientific Review”].  
32 Ishii, supra note 15, at 151; Mitochondrial Donation: Correspondence Received Relating to 
the Evidence Hearing on 22 October 2014, SCI. & TECH. COMM., HOUSE OF COMMONS at 15 
(2014), https://www.parliament.U.K./documents/commons-committees/science-
technology/Mitochondrial%20donation/MITCorrespondence.pdf [hereinafter “U.K. 
Correspondence”].   
33 FDA Brief, supra note 13, at 9. 
34 Baylis, supra note 29; FDA Brief, supra note, at 10. 
35 Sarah Fogleman et al., CRISPR/Cas9 and Mitochondrial Replacement Therapy: Promising 
Techniques and Ethical Considerations, 5 AM. J. OF STEM CELLS 39 (2016). 
36 Amato et al., supra note 19, at 32. 
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III. International Law and Policy Pertaining to Germline Modification 
Contrary to the common parlance discussing the procedure, MRT does not replace 
mitochondria or “swap in healthy mitochondria,” but instead constitutes transferring the nucleus 
containing 20,000 genes from one oocyte or zygote to another.37  This procedure is more 
accurately classified as nuclear genome transfer and a modification of the human germline, 
which has prohibited by numerous declarations, directives, and laws promulgated by 
international entities and other nations.38  
A. United Nations Position on Germline Modification 
The United Nations Universal Declaration on the Human Genome and Human Rights has 
declared that the “human genome underlies the fundamental unity of all member of the human 
family…it is the heritage of humanity.”39  In Article 5, the Declaration states “research, 
diagnosis, or treatment affecting an individual’s genome shall be undertaken only after rigorous 
and prior assessment of potential risks and benefits,” this  intervention requires informed consent 
that the procedure would be guided by the individual’s best interest, and if the individual does 
not have the capacity to consent then the intervention may only be carried out for the direct 
benefit or, alternatively, “pose such minimal risk and burden” to the individual that the research 
is “compatible with the protection of the individual’s human rights.”40 These articles do not 
distinguish between somatic and germline interventions, but suggest a high level of scrutiny 
                                                          
37 3-Person IVF A Resource Page, CTR. FOR GENETICS AND SOCIETY, 
http://www.geneticsandsociety.org/article.php?id=6527. 
38Id.; Isasi et al., supra note 15; Ishii, supra note 15; Araki & Ishii, supra note 15. 
39 Universal Declaration on the Human Genome and Human Rights, UNITED NATIONS SCI. 
EDUC., SCI. & CULTURAL ORG., UNITED NAT’L GEN. ASSEMB. (1997), 
http://www.unesco.org/new/en/social-and-human-sciences/themes/bioethics/human-genome-
and-human-rights/.  
40 Id.  
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regarding risks must be applied in this area of research and individual consent must be 
prioritized.  These points interpreted together would likely prohibit germline engineering based 
both on the risk profile and inability for future generations to consent to modification of their 
genomes.     
In subsequent discussions specifically pertaining to the human genome and the 
appropriate uses of emerging technology, the International Bioethics Committee of the United 
Nations Educational, Scientific, and Cultural Organization (“UNESCO”) promulgated additional 
guiding principles.41  Importantly, the International Bioethics Committee noted that the human 
genome does not constitute raw material that scientists may manipulate at leisure, cautions 
against genetic reductionism and parsing component parts when attempting to treat the complex 
nature of human disease while noting the uncertain and highly variable state of the genome  and 
the unpredictable impact of modifications.42 Recognizing the transnational nature of research, the 
International Bioethics Committee also directly stated that we should renounce the possibility of 
scientists acting alone and discourage avenues of regulatory circumvention, in this instance, 
through reproductive tourism.43  Finally, the International Bioethics Committee called upon the 
media to avoid sensationalist journalism, asserted the media’s duty to promote scientific literacy, 
and cautioned that the direction and limitations of science should not be determined by market 
forces.44   
Together, these crucial points recognize the complexities of human health and appear to 
                                                          
41 Report of the IBC on Updating Its Reflection on the Human Genome and Human Rights, 
UNITED NATIONS SCI. EDUC., SCI. & CULTURAL ORG., UNITED NAT’L GEN. ASSEMB. (2015), 
http://unesdoc.unesco.org/images/0023/002332/233258E.pdf. 
42 Id. at 4. 
43 Id. at 3-4. 
44 Id. at 4. 
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caution against precisely the campaign occurring in support of MRT – a risky experimental 
procedure that separates and patches together building blocks of an embryo heralded by the 
media a miracle therapy – wherein the media praises physicians engaging in fertility tourism to 
allegedly dodge unnecessary regulations while generating publicity and expanding a highly 
profitable commercial market into for patients with infertility. 
B. Council of Europe Position on Germline Modification 
The Council of Europe has also promulgated several documents pertaining to 
prohibitions on germline interventions.  The Council of Europe’s Convention on Human Rights 
and Biomedicine states “an intervention seeking to modify the human genome may only be taken 
for preventive, diagnostic, or therapeutic purposes, and only if its aim is not to introduce any 
modification in the genome of any descendants.”45  This Convention clearly demarcates 
therapeutic somatic interventions as potentially permissible, but unequivocally distinguishes that 
any germline or inheritable modifications are prohibited.  Aligned with this prohibition, in 2001 
the European Union promulgated a directive on clinical trials that further specified, “No gene 
therapy trials may be carried out which result in modifications to the subject’s germline genetic 
identity.”46  Both statements prohibit both clinical trials designed to investigate MRT because it 
would result in germline modifications. 
 
 
                                                          
45 Article 13, Convention on Human Rights and Biomedicine, COUNCIL OF EUROPE (1997), 
https://rm.coe.int/CoERMPublicCommonSearchServices/DisplayDCTMContent?documentId=0
90000168007cf98. 
46 Article 9, Directive 2001/20/EC, COUNCIL OF EUROPE (2001), 
http://ec.europa.eu/health//sites/health/files/files/eudralex/vol-
1/dir_2001_20/dir_2001_20_en.pdf. 
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C. Comparing U.S. Governance Pertaining to Germline Modification to Other 
Nations 
Globally, approximately forty countries47 including Canada,48 Germany,49 France,50 
Switzerland,51  Sweden,52 and Italy53 have adopted legislation prohibiting germline intervention 
on embryos.54  Laws enacted in the aforementioned nations not only prohibit germline or 
heritable modification, but such actions constitute criminal violation subject to fines and or 
imprisonment.  Unequivocally prohibiting and criminalizing an action communicates the 
egregiousness, potential for harm, and social unacceptability of such an action in these nations.  
Unlike the widespread alarmist rhetoric that the United States is “falling behind” and failing to 
invest in promising genomic technologies, these laws demonstrate the opposite: many countries 
acknowledge the lure of technology, but renounce risky experiments that cross the historical 
                                                          
47 See Araki & Ishii, supra note 15, at Table S1: Policies on Human Germline Gene Modification 
for Reproduction Excluding Reproductive Cloning. 
48 Assisted Human Reproduction Act § 5 (2004); Assisted Human Reproduction Act § 60 (2004). 
49 Embryo Protection Act, Federal Law Gazette, Part I, No.69 (1990).  
50 Research on Embryos, Bioethics Law, Code of Public Health Article L2151-5 (2011); 
Absolute Prohibition on Creating Transgenic Embryos and Chimeras, Bioethics Law, Code of 
Public Health. Article L2151-2 (2011); see also Sylvain Beaumont & Sandra Tripathi, France’s 
Loi du 7 Julliet 2011 Clarifies The Human Embryonic Research System, LIFE SCIENCES 
BULLETIN, Fasken Martineau (Aug. 2, 2011), http://www.fasken.com/files/Publication/ad92fa84-
d869-497e-80d7-071bfef919e5/Presentation/PublicationAttachment/f3b681c6-78fc-4379-aa6d-
19456049955c/Life%20Sciences%20Bulletin%20-%20Beaumont-Tripathi%20-
%20August%202%202011.pdf. 
51 Article 35, Federal Act on Medically Assisted Reproduction, Federal Assembly of the Swiss 
Confederation (1998).  
52 See Sections 3-4, The Genetic Integrity Act, Swedish Code of Statutes no.2006:351 (2006). 
53 Article 13, Rules of Medically Assisted Procreation, No. 40 (2004).  
54 Some laws prohibit germline modification to any embryo, some prohibit modification for 
implantable embryos. See also Isasi et al., supra note 15; Anna Zaret, Editing Embryos: 
Considering Restrictions on Genetically Engineering Humans, 67 HASTINGS L. J. 1805, 1810-11 
(2016).   
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bright line of manipulating future generations.55 
Canada’s Assisted Human Reproduction Act in particular contains notable provisions that 
prioritize central concepts to guide appropriate application of technology relating to reproductive 
and genomic interventions.56  Section 2 of Canada’s Assisted Human Reproduction Act states 
that the “health and well-being of future children must be given priority,” and that the Parliament 
seeks to uphold the “protection of human health, safety, dignity and rights” relating to the use of 
assisted reproductive technologies, and prohibits compensation for oocyte donors due to the 
potential for health risks and exploitation.57  Further, Subsection (g) of Section 2 explicitly states 
“the integrity of the human genome must be preserved and protected.”58  These provisions 
together recognize the commercial nature of technology and declare neither commercial nor 
other interests, such as the technological imperative, ought to drive the adoption of technology 
and modification of the germline is prohibited.59 
In 2015, the National Academy of Sciences, Engineering and Medicine, the Royal 
Society, and the Chinese Academy of Sciences sponsored the International Summit on Human 
Gene Editing to discuss broader issues relating to gene editing and modification of the 
                                                          
55 The Science and Ethics of Genetically Engineered Human DNA, Hearing Before the 
Subcommittee on Research and Technology, 114TH CONGRESS (2015).  Rather than discussing 
human dignity or risks of technology, attendees at this hearing pled for federal funding, noted the 
global market competitiveness, and asserted regulation must not “squelch the science” or the 
United States would “fall behind.”  Attendees also mischaracterized the experimental nature of 
germline modification, asserting that parents merely have a “desire to protect their children” [by 
modifying their genomes] and there may be a time when we consider it unethical not to modify 
our children’s genomes. 
56 Assisted Human Reproduction Act § 2 (2004). 
57 Id.  
58 Id.  
59 Id.  
13 
 
germline.60  Though the meeting discussed recent research relating to other genetic modification 
technologies such as CRISPR, many of the considerations are also applicable to MRT.  The 
National Academies Press published a meeting summary that called for a moratorium on clinical 
germline modification, noting safety and efficacy issues are unresolved, and such action could 
impose irreversible risks and long term harms.61  Commentators at the International Summit also 
recognized the potential for economic interests to capitalize on the global nature of science and 
technology, where technology adopted in one location prompts international forum shopping. 62   
Situating the actions of Dr. Zhang and Dr. Zukin against the backdrop of the global 
climate where many nations not only prohibit, but impose criminal penalties for these risky 
experiments it becomes exceedingly clear how radical these events were.  Numerous scientists, 
bioethicists, and policymakers swiftly voiced vehement opposition, asserting that “going rogue” 
was “irresponsible and unethical” because it combined reproductive tourism promoting 
commercial interests with “highly experimental science.”63 These characterizations stand in stark 
contrast to media articles praising Dr. Zhang, decrying slow “progress” in the United States, and 
                                                          
60 International Summit on Human Gene Editing: A Global Discussion, NAT’L ACAD. OF SCI., 
ENG’G & MED. (2015), https://www.nap.edu/catalog/21913/international-summit-on-human-
gene-editing-a-global-discussion. 
61 Id. 
62 Id. 
63 Comment on the Use of Mitochondrial Manipulation Techniques by US Scientists in Mexico, 
CTR. FOR GENETICS & SOC’Y (Sept. 27, 2016),  
http://www.geneticsandsociety.org/article.php?id=9697; Comment on “3-Person IVF” 
Procedures Reportedly Conducted in Ukraine, CTR. FOR GENETICS & SOCIETY (Oct. 10, 2016), 
http://www.geneticsandsociety.org/article.php?id=9730; 3-Person IVF A Resource Page, supra 
note 37; see also Paul Knoepfler, First 3-Person IVF Baby Born Via “Rogue” Experiment in 
Mexico Clinic? The Niche (Sept. 27, 2016), https://ipscell.com/2016/09/first-3-person-ivf-baby-
born-via-rogue-experiment-at-mexico-clinic/; Pete Shanks, Wrong Steps: The First One From 
Three, DECCAN CHRON. (Oct. 2, 2016), http://www.deccanchronicle.com/lifestyle/viral-and-
trending/021016/wrong-steps-the-first-one-from-three.html. 
14 
 
intimating these procedures constitute an effective “treatment, or even cure.”64 Perpetuating such 
bias and gross mischaracterization in scientific media deliberately skews the framing of the 
discussion as an intentional means to gain favor and direct the outcome. This campaign not only 
lacks transparency, but promotes a policymaking process premised upon inaccurate scientific 
information and false characterizations of global legal consensus that renders it egregiously 
unethical.  Furthermore, Dr. Zhang’s actions to evade regulatory structures in the United States 
by performing MRT in Mexico were precisely the type predicted by the International Summit, 
and will likely continue to occur based on a public statement from the New Hope Fertility Center 
branch in Mexico promising plans for more “three-parent babies.”65   
IV. United Kingdom’s Process to Permit MRT 
In 2013, the Human Fertilisation and Embryology Authority (HFEA) began its 
consultation process to consider the process of permitting MRT.  The HFEA is the entity in the 
U.K. that oversees reproductive technologies such as IVF and commercial surrogacy and 
promulgates criteria for licensing fertility clinics.66  During the policymaking process in the 
United Kingdom, scientists, bioethicists, and other stakeholders raised concerns about how both 
the British media, the U.K. Department of Health, and the HFEA presented MRT to the public.67 
                                                          
64 Ossola, supra note 6; Michael Le Page, Mexico Clinic Plans 20 “Three-Parent” Babies in 
2017, NEW SCIENTIST (Dec. 9, 2016), https://www.newscientist.com/article/2115731-exclusive-
mexico-clinic-plans-20-three-parent-babies-in-2017/. 
65 Id. 
66 Castro, supra note 13; 3-Person IVF: A Resource Page, supra note 37; About the HFEA, 
Human Fertilisation and Embryology Authority, http://www.hfea.gov.U.K./25.html.  
67 See generally Steve Connor, Scientists Accuse Government of Dishonesty Over GM Babies in 
Its Regulation of New IVF Technique, THE INDEPENDENT (July 28, 2014), 
http://www.independent.co.U.K./news/science/exclusive-scientists-accuse-government-of-
dishonesty-over-gm-babies-in-its-regulation-of-new-ivf-9631807.html; Stuart Newman, 
Deceptive Labeling of a Radical Embryo Construction Technique, HUFFINGTON POST (Dec. 1, 
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At the start of this initial period of consultation, forty one signatories including notable 
bioethicists, scholars, and scientists published a letter to the editor of The Times expressing alarm 
over HFEA’s proposal for MRT.68  This letter noted the broad global consensus against germline 
interventions, stated MRT would “cross the Rubicon” and open the door to other germline 
modifications, and may pose unforeseen consequences.69  The authors also noted the 
transnational implications and urged HFEA against acting alone, declaring the U.K. must 
consider its “international responsibilities.”70  Despite exceedingly clear widespread opposition 
and breach of longstanding international precedent against germline modifications, HFEA 
continued its deliberative process. 
A. HFEA Review and U.K. Department of Health  
In 2014, the HFEA published a Review of the Safety and Efficacy of Methods to Avoid 
Mitochondrial Disease Through Assisted Conception (“HFEA Review”).71  The HFEA Review 
referenced a provision from an amendment passed in 2008 that defined a “[permitted] egg or 
embryo” as one that has been altered through a technique designed to avoid the transmission of 
mitochondrial disease.72  Unlike the indicated use under consideration in the United States, the 
regulation in the U.K. only pertains to MRT for the purpose of avoiding mitochondrial disease 
and the HFEA Review specifies it does not currently encompass treatment for infertility.    The 
HFEA Review reflected a favorable option toward MRT, basing its presumptions on measuring 
low preliminary levels of carryover maternal mutant mtDNA, asserting the methods of MRT are 
                                                          
68 Letter to the Editor, Alarm Over Genetic Control of Embryos, THE TIMES (March 20, 2013), 
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71 HFEA Scientific Review, supra note 31. 
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“efficient” and “reassuring.”73  The HFEA Review also characterized that existing animal 
models demonstrated “good progress”74 and concluded “the evidence does not seem to suggest 
the techniques are unsafe.”75   
During this process, the U.K. Department of Health issued several reports and statements 
describing the process of MRT that strategically characterized the procedure in a manner to 
avoid scrutiny for the crossing the bright line prohibition against germline modifications.76  First, 
the U.K. Department of Health conceded that MRT constituted a germline modification, but 
argued that it did not pose a genetic modification because there is not an agreed upon definition 
of what a genetic modification entails.77  The U.K. Department of Health suggested modifying 
mtDNA and performing nuclear genome transfer does not alter the oocyte or embryo’s genetic 
information, asserting mtDNA merely functions as batteries of the cell.78  Second, the U.K. 
Department of Health extended this presumption by maintaining MRT would not contravene the 
Universal Declaration on the Human Genome and Human Rights’ prohibition against germline 
interventions because it serves a therapeutic corrective purpose so it does not harm human 
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76 Connor, supra note 67; Mitochondrial Donation: A Consultation on Draft Regulations to 
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https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/285251/mitochon
drial_donation_consultation_document_24_02_14_Accessible_V0.4.pdf. 
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dignity.79  This bizarre twisting of terminology not only distorted the characterization of MRT to 
the public, but fueled scientifically incorrect descriptions in British media aimed at garnering 
public support. 
 The HFEA Review acknowledged the potential for complications pertaining to safety 
and efficacy, but unilaterally disregarded what the scientific community has described as 
numerous substantial barriers.80 For example, the HFEA Review addressed differential 
segregation and maternal bottleneck that could result in increasing levels of heteroplasmy during 
the offspring’s course of development in different tissues, and increasing levels of heteroplasmy 
through subsequent generations.81  In response to this possibility, the HFEA Review responded 
“there is little evidence of this occurring.”82  Importantly, HFEA’s evaluation is based on the 
premise that PGD testing of the blastocyst (cells in early stages of embryonic development) 
constitutes an accurate representation of both lifetime heteroplasmy in all subsequently 
developed tissues and health of the eventual offspring.83   
The HFEA cited animal studies using macaque models where about half of the macaque 
embryos appeared to develop normally as evidence of “good progress” that MRT appeared to 
work.84 In response to the half of embryos following MRT that did not develop correctly, HFEA 
disregarded these findings, asserting there may be “some differences in embryo development, but 
nothing has been found to raise concerns of safety.”85  The HFEA also noted the concern that 
there may be incompatibility arising from mixing mtDNA from two sources, but concluded 
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80 See generally U.K. Correspondence, supra note 32; FDA Meeting, supra note 11. 
81 HFEA Scientific Review, supra note 31, at 26. 
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83 Id. at 13. 
84 Id. at 20. 
85 Id. at 20.  
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mixing two sources of mtDNA would not pose any complications to interaction with nDNA or 
cell function.86  As support for its conclusion, HFEA observed that children from mixed race 
parents (one source of maternal mtDNA) do not exhibit higher percentages of mitochondrial 
disease.87 
B. Public Comments in the U.K. Policymaking Process 
During this process, the U.K. House of Commons Science and Technology Committee 
held a hearing on the scientific evidence for MRT and published written correspondence from 
numerous scientists, physicians, bioethicists, and other stakeholders.88  Although a minority of 
comments lent support to HFEA’s proposed direction and even asserted it would be unethical not 
to use MRT,89 the majority of public comments fervently opposed MRT precisely based on 
unsettling and unresolved issues pertaining to evidence for its safety and efficacy.90  A number of 
comments highlighted the unpredictability of differential segregation and maternal bottleneck, 
asserting that attempting to measure carryover of maternal mtDNA in the blastocyst via PGD 
was an ineffective and improper proxy for predicting long term levels of heteroplasmy and health 
outcomes.91  Comments also opposed HFEA’s characterization of animal models as successful, 
noting that the 52% of animal embryos that did not develop correctly demonstrated chromosomal 
abnormalities, and questioned whether these findings may result in unexamined differences in 
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88 U.K. Correspondence, supra note 31.  
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the embryos that scientists proclaimed were developing normally.92  
In addition to these responses, multiple comments disputed HFEA’s conclusion 
pertaining to the compatibility of two sources of mtDNA and epigenetic effects resulting from 
transfer of the nuclear genome from one oocyte or embryo to another.93 A number of interested 
parties, including the Council for Responsible Genetics, Human Genetics Alert, and several 
scientific experts submitted similar assessments noting evidence for extensive communication 
between mtDNA and nDNA expression.94  Disrupting mtDNA functioning and cross-talk to 
nDNA directly influences DNA methylation and chromosomal gene expression.95  That is, 
mitochondria are not merely batteries supplying energy to the cell that can be deftly exchanged, 
but part of a complex interwoven system necessary for the entire organism’s subsequent 
development.96  These observations also highlighted the unprecedented risks related to embryo 
manipulation, noting the more extreme the level of physical manipulation, the higher the 
potential for physical damage to the embryo or epigenetic changes resulting from the process of 
physical manipulation  and the risk for functional and developmental health deficits.97 
Notably, these comments independently evaluated the status of scientific evidence 
underlying HFEA’s conclusion that the techniques appear “not unsafe” and concluded the 
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opposite: these techniques are likely to be unsafe.98  Human Genetics Alert questioned why 
HFEA would blatantly dismiss substantial categories of potential risks, alleging its process was 
based on “disastrously flawed scientific assumptions,” charged that the public consultation 
process was “biased” because HFEA did not accurately describe MRT, and asserted the 
amendment lacked public support.99  Cell biologist Professor Stuart Newman reiterated Human 
Genetics Alert’s objection to improper framing to the public because HFEA the technology as 
“mitochondrial donation.” 100 Newman implored HFEA to appropriately label the technology as 
nuclear genome transfer, pointing out this technique creates a child through an evolutionary 
unprecedented experiment because it removes 20,000 chromosomes from one ooctye or embryo 
and transfer this nDNA into another oocyte or embryo.101  Critics exhorted that “harmful 
consequences of these methods could impair entire generations,” and issued proclamations that 
HFEA’s conclusions were both “incomplete and unsubstantiated.”102  Reiterating this warning, 
cell biologist Professor Paul Knoeplfer proclaimed the U.K. was on the verge of an “historic 
mistake.”103 
C. The Role of British Media 
The press quickly rebounded and parroted the U.K. Department of Health and HFEA’s 
strategic framing to garner support for the 2015 amendment to the Human Fertilisation and 
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Embryology Act that would expressly regulate MRT.104  Professor Julian Savulescu compared 
MRT to a “micro-organ transplantation,” alleging there is “no sound basis to oppose MRT” 
because it constitutes a “cure” so infants can be born without mitochondrial disease.105  An 
article in the Guardian appealed to the pathos of parental suffering touting MRT as a method to 
prevent incurable genetic disease and “[save] families needless misery” over ill-advised 
objections of religious groups.106  Both Savulescu and an article in the New York Times chided 
opposition to MRT, scoffing that “preventing medical advancement” is so illogical, it could only 
be based on being improperly informed.107   
These pieces in the media not only reinforced incorrect scientific characterizations set 
forth by the U.K. Department of Health and the HFEA, but employed a dangerous precedent of 
classifying legitimate scientific dissent supported by credible evidence outside the parameters of 
acceptable discussion.  Elevating the U.K. Department of Health and HFEA’s presumptions as 
sacrosanct is not only scientifically disingenuous, but dangerous to the honesty and transparency 
required in the policymaking process.   
D. Outcome of the U.K. Policymaking Process and Lessons for the U.S. 
In November of 2016, HFEA recommended “cautious use” of MRT subject to a set of 
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conditions where individual fertility clinics must apply for a license to conduct the procedure.108  
Following HFEA’s decision, the Newcastle Fertility Center announced its intent to submit an 
application for a license and begin the process of offering MRT to its fertility patients meeting 
the criteria set forth by HFEA.109 
A number of key points emerged during the lengthy policymaking process in the U.K. 
that provides perspective when considering the process in the U.S.  When HFEA and the U.K. 
Department of Health initially raised the possibility of MRT, bioethicists, scholars, and scientists 
noted MRT would breach the broad global consensus against germline modifications and urged 
the government to reconsider.  To initially gain favor, the HFEA and the U.K. Department of 
Health strategically named the techniques MRT rather than accurately describing it as nuclear 
genome transfer.  Relabeling a procedure by comparing it to an acceptable practice such as organ 
donation or replacing batteries obfuscated the gravity and risk involved.  During the consultation 
process, numerous scientists provided testimony and correspondence at length relating to safety 
and efficacy.  These scientists objected to HFEA’s conclusions based on available evidence, 
finding not merely a lack of consensus pertaining to safety and efficacy, but that the available 
scientific evidence demonstrated how unsafe MRT is.  Despite objections based on international 
governance, evidence demonstrating insufficient safety and efficacy, and lack of public 
consensus, British Parliament passed the amendment that would permit HFEA to license fertility 
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clinics to offer MRT reflecting a massive disconnect in the legal, scientific, and policymaking 
process. 
V. United States Governance and Policymaking Related to MRT 
Similar to the United Kingdom, the United States has undertaken steps to begin the 
process of permitting MRT.  There is currently no legal prohibition against germline 
modification in the United States.110  In 2014, the FDA convened meetings to discuss the 
medical rationale and scientific evidence pertaining to MRT for both the prevention of 
mitochondrial disease and the treatment of infertility.111  In 2015, the White House announced 
that germline modifications constituted a line “that should not be crossed at this time”112 and the 
NIH issued a statement it would not fund research involving germline modification.113  However, 
in 2016, the National Academies of Science, Engineering, and Medicine issued a report (NAS 
Report) on the ethical and policy implications of MRT and concluded it is ethically permissible 
to conduct clinical investigations subject to a set of conditions.114  Based on another subsequent 
report issued by NAS endorsing therapeutic germline modification through gene editing, it 
appears likely that the governance climate in the U.S. favors MRT, and any present prohibitions 
related to federal funding may potentially be lifted in the future.115 
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A. Applicable FDA Regulations to MRT 
In the United States, any clinical investigational use of MRT falls under the purview of 
the FDA. Under the Public Health Service Act (“PHSA”), the FDA regulates human cell and 
tissue products (“HCT/Ps”), which refers to articles “containing or consisting of human cells or 
tissues that are intended for implantation, transplantation, infusion, or transfer into a human 
recipient.”116 These regulations are designed to prevent contamination and communicable 
disease rather than to ensure safety and efficacy.117  They impose several requirements such as 
registering the HCT/Ps with the FDA and promulgating standards for Good Tissue Practices, 
including monitoring the procedures, facilities, processing equipment, and supplies and reagents 
used in the manufacturing process.118 Under the HCT/P system set forth in 21 CFR §1271, the 
FDA classifies different types of human cells, tissues, and cellular and tissue-based products into 
categories for regulation based on the public health risks they pose: (1) products not subject to 
HCT/P regulations, (2) HCT/Ps regulated under Section 361 of the PHSA, and (3) products 
posing the most risk that are to be regulated stringently as a biological product or drug.119   
In the late 1990s and early 2000s several clinics began to conduct cytoplasm transfers.  
These procedures differed from MRT currently under consideration because the procedure 
involved injecting cytoplasm from a donor containing mitochondria into the mother’s oocyte and 
did not involve nuclear genome transfer.120  Though technically distinct, these procedures 
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resulted in the birth of seventeen children, two of whom had chromosomal abnormalities and one 
whom had with pervasive developmental disorder.121  Only cursory follow-up has been 
conducted on the health of the resulting children, but the incident prompted the FDA to assert its 
jurisdiction over this area of reproductive technology.122  
In 2001, the FDA expanded its definition of “human cells, tissues, or cellular or tissue 
based products” HCT/Ps to include semen or other reproductive tissue.123 This required fertility 
clinics handling gametes and reproductive tissue to comply with requirements for laboratory 
registration, minimal procedures to screen HCT/Ps for communicable disease, and good 
manufacturing procedures.124  FDA considers standard procedures such as IVF “minimal 
manipulation” and subject only to the requirements set forth in Section 1271.125   
Around this time in 2001, the FDA sent a warning letter to the scientists conducting 
cytoplasm transfers, asserting clinical research involving the transfer of genetic material must be 
conducted pursuant to an investigational new drug application.126  In 2009, the FDA issued 
guidance affirming this position, asserting procedures currently used for MRT including 
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maternal spindle transfer and pronuclear transfer that involve the transfer of genetic material 
constitute “more than minimal manipulation” and require the investigator to submit an 
investigational new drug application.127  Thus, clinical investigation of MRT would require 
“submitting preclinical data and information on product safety, details about technique, and 
proposed clinical investigation protocols” pursuant to an investigational new drug application.128  
If the FDA were to approve MRT and license its use for only one indication such as the 
prevention of mtDNA disease, clinics would be able to expand the scope of indications through 
off label use for other uses such as infertility and therapeutic energetic correction.129  As with 
other drugs and biologics, off label use dramatically expands both the potential market and 
opportunity for commercial profit. 
B. Federal Funding Considerations 
In addition to federal regulations set forth by the FDA, clinical investigation using 
embryos would be subject to federal funding restrictions and subject to state laws pertaining to 
research on embryos, some of which appear to prohibit MRT.130  At the federal level, the 
Dickey-Wicker Amendment prohibits the use of federal funds for research in which an embryo is 
created or destroyed.131  However, some state laws as well the Dickey-Wicker Amendment 
contain exceptions in circumstances where the research on the embryo would provide benefit to 
the embryo or if the investigation is defined as therapeutic research designed to lead to gestation 
and birth of that embryo.132  Finally, the Consolidated Appropriations Act of 2016 currently 
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prohibits the FDA from using federal funds to consider applications for an exemption for 
investigational use of a drug or biological product “in research in which a human embryo is 
intentionally created or modified to include heritable genetic modification.”133  Although the 
Consolidated Appropriations Act appears to prohibit the FDA from using federal funding to 
review applications for MRT, the NAS Report recently questioned whether MRT constitutes 
heritable germline modification, asserting it would require additional legal analysis which makes 
the application of the spending prohibition uncertain.134  
C. FDA Meetings to Discuss Safety, Efficacy, and Risks of MRT 
In 2014, the Cellular, Tissue, and Gene Therapies Advisory Committee of the FDA held 
a meeting titled “Oocyte Modification in Assisted Reproduction for the Prevention of 
Transmission of Mitochondrial Disease or Treatment of Infertility,” (“MRT Meeting”) which 
addressed the intersecting regulatory and scientific considerations pertaining to safety and 
efficacy of MRT based on available data and the state of scientific knowledge.135  In conjunction 
with this meeting, the FDA published a briefing document (“MRT Brief”) on the same 
summarizing the proposed methodology and areas of concern pertaining to safety.136  
1. Determining Efficacy and Defining Success  
During the MRT Meeting, the FDA addressed the patient population and indicators of 
how to define success.  Significantly, the MRT Meeting not only addressed MRT for the 
prevention of mtDNA disease, but also for treating infertility.  Unlike other potential clinical 
trials where the FDA determines calculations of safety and efficacy for the intended patient, the 
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subject would be created using the proposed methodology.  Past reports issued by the President’s 
Council on Bioethics and the NAS have asserted that because the clinical investigation occurs on 
the embryo, it would not constitute human subjects research as defined in the Common Rule.137  
Under this interpretation, any research conducted prior to implantation need not meet the 
requirements set forth in the Common Rule such as its specific requirements for informed 
consent and the provision that the benefits must be greater than the risks as applied to the 
resulting child.   
Participants at the MRT Meeting posed the question of how to define efficacy, with some 
participants proposing that efficacy can be determined from a viable pregnancy.138  During the 
course of the meeting, however, commentators noted lack of scientific consensus pertaining to 
defining the parameters of efficacy, and some commentators urged testing the blastomere (cells 
in early stages of embryonic development) for viability is not indicative of the health of the child 
and subsequent offspring.139  One scientist also noted that testing a sample is not indicative of the 
rest of the inner cell mass, meaning different levels of heteroplasmy may exist, and even 
subsequently develop at varied rates in different tissues though stages of development and the 
child’s life.140  Based on those metrics, efficacy could not be determined merely from a viable 
pregnancy but instead requires examining the health of the child and potentially the child’s 
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offspring.  Scientists and scholars have commented on this bind, observing that we simply cannot 
know with certainty whether MRT would be safe and effective because germline intervention 
necessarily imposes substantial risk that cannot be eliminated.141   
2. Current Barriers to Safety and Efficacy in MST and PNT  
Throughout the course of the meeting, the participants discussed a number of barriers to 
safety and efficacy arising from mitochondrial biology described supra in Section II. 
a. Maternal Bottleneck, Segregation, and Heteroplasmy 
According to participants at the MRT Meeting, animal models have not sufficiently 
addressed maternal bottleneck, where levels of mutant mtDNA can increase from one generation 
to the next.142  Currently, it is difficult to predict the child’s pattern of inheritance based on the 
mother’s percent of mutated mtDNA.  Thus, a mother presenting without mtDNA disease based 
on her low level of heteroplasmy could give birth to a child with a high level of heteroplasmy 
that reaches the threshold to be affected by mtDNA disease.  Furthermore, maternal bottleneck 
can increase the percent heteroplasmy in each subsequent generation.143  A blastomere, or even a 
child that initially demonstrates low levels of heteroplasmy from mutant mtDNA carryover who 
appears healthy may pass on amplified risk to future generations who would present with 
mtDNA disease.144  Some evidence exists to suggest these risks would particularly affect female 
generations.145  These observations pertaining to maternal bottleneck mirror the shortcomings of 
PGD as a method of currently screening embryos at risk for mtDNA disease, and underscore the 
                                                          
141 Baylis, supra note, at 533; Lanphier et al., Don’t Edit the Human Germline, 519 NATURE 410, 
411 (2015) (Discussing the uncertainty of germline modifications, stating “The precise effects of 
genetic modification to an embryo may be impossible to know until after birth.”).  
142 FDA Meeting, supra note 11, at 34-35, 141-142; FDA Brief, supra note 13, at 7, 21. 
143 Id.  
144 Id. at 132-35. 
145 FDA Brief, supra note 13, at 21, 39. 
30 
 
inability to predict efficacy based on testing the blastomere.146  Additionally, even testing adult 
tissues may demonstrate no mtDNA mutations, but mtDNA mutations could be present in the 
germ cells of the individual and be passed on through reproduction to the subsequent generation, 
and increase from one generation to the next.147 
Currently, effective methodology does not exist to account for testing the fluid mutations 
of mtDNA in every tissue over the human lifespan.148 Following the procedure of MST or PNT, 
the combination of maternal mtDNA carried over into the donor oocyte continues to divide and 
increase in each cell of the growing organism.  Biologist Dr. Shoukhrat Mitalipov, whose lab had 
been conducting investigations based on animal models, asserts segregation in tissues drifts 
toward homoplasmy, which would result in the donor’s mtDNA dominance.149  Despite 
Mitalipov’s testimony at the MRT Meeting declaring favorable genetic drift, this presumption is 
not universally shared by other experts.150  According to other research, there is little known 
about the dynamic by which mtDNA evolves within an organism, because one haplotype (the 
group of genes in mtDNA−here there is the maternal haplotype of mtDNA and the donor 
haplotype of mtDNA) could replicate faster than the other, which could result in a dramatic 
increase in the level of heteroplasmy.151   
Segregation and replication of mtDNA occurs according to its own evolutionary system, 
which makes predicting subsequent levels of heteroplasmy difficult.152  Even if segregation 
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initially demonstrates favorable drift toward the donor’s mtDNA, these levels may jump 
unpredictably, or segregate at different levels in tissues throughout the body.153  Levels of 
mtDNA in the child’s blood may reflect a low percent of heteroplasmy, but genetic drift can 
cause segregation toward the mother’s mutated mtDNA in specific tissues or organs, wherein the 
child may experience diseases arising in those systems.154  Specifically, one study demonstrated 
initial carryover rates of maternal mtDNA of 1.2% unexpectedly increased to 53% when 
studying embryos in culture, leading one biologist in favor of MRT to admit that “it would defeat 
the purpose of doing mitochondrial replacement” and “it is wise not to move forward with this 
uncertainty.”155   Finally, segregation occurs throughout the lifespan of the individual which 
means low levels of the mother’s mtDNA in the child’s blood or partial tissue testing would also 
not reflect the possibility of increasing levels of heteroplasmy later in life resulting in latent 
presentation of mitochondrial disease.156  Thus, statements that claim heteroplasmy would not 
pose a problem if initial carryover of mtDNA appears unsupported by existing evidence.157 
In addition to maternal bottleneck and segregation shifting the percent of mutant mtDNA, 
mutations in mtDNA that cause heteroplasmy naturally occur through aging and increases 
throughout one’s life.158  In addition to mutated mtDNA, both de novo (new) mutations and 
mutations to nDNA occur that can result in mitochondrial dysfunction.159   Some scientists 
hypothesize there are naturally occurring levels in heteroplasmy in everyone contributing to 
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common disease such as heart disease, diabetes, and neurodegeneration.160  These mutations 
suggest two points: first, there are other factors influencing the evolution of mtDNA; and second, 
attempting to find a donor without mtDNA mutations would be difficult.161 
b. Haplotype Incompatibility 
Participants at the MRT Meeting also raised concerns relating to the potential for 
incompatibility arising from mixing two haplotypes of maternal mtDNA and donor mtDNA.162  
Although proponents of MRT state that haplotype mixing does not appear to result in 
abnormalities, these presumptions rest upon extrapolating projections that rely on two parent 
scenarios.163  Some scientific evidence suggests that segregation appears affected by genetic 
distance between haplotypes and when haplotypes of maternal mtDNA and donor mtDNA are 
mixed, reversion toward maternal mtDNA occurs.164  In animal models, mixed mtDNA has 
resulted in immune rejection, susceptibility to diseases of metabolism, and deficits in 
performance and learning capabilities.165 
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c. Cross-talk between mtDNA and nDNA 
Contrary to the media representations that mtDNA’s role is negligible except for 
unidirectional provision of energy, participants at the MRT meeting as well as substantial 
additional evidence demonstrate what scientists refer to as cross-talk, symbiosis, and co-
evolution between mtDNA and nDNA.166  Mitochondrial DNA not only provide energy, but 
control metabolic processes, programs cell growth and apoptosis, and impacts nDNA 
expression.167  Scientists have described the interaction between mtDNA and nDNA as a 
complex evolutionary model, where the genome should be considered comparable to an 
ecosystem where every interconnected element affects the functioning of the whole.168  
Mitochondrial DNA not only functions as a source of energy, but affects a wide range of cellular 
functioning and how nDNA is expressed.169  Disrupting the cross-talk between mtDNA and 
nDNA in animal models results in adverse outcomes and disturbs crucial mitochondrial 
processes.170  Current research suggests interference in the communication between mtDNA and 
nDNA can negatively affect individual development, behavior, susceptibility to disease, and 
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fertility.171  As one scientific article summarized, “perturbation of the mito-nuclear interactions . 
. . generally attracts grave consequences.”172  
d. Animal and In Vitro Models 
Based on the current knowledge of animal models, participants at the MRT Meeting 
raised the same concerns as in the U.K. discussions about characterizing the current evidence and 
limitations of current studies.173  Proponents have highlighted animal models using a small 
population of macaques, finding low initial percentages of heteroplasmy and declaring “positive 
results” that the offspring are “healthy.”174  However, participants at the MRT meeting noted 
several shortcomings: those studies relied on a small sample and may miss problems that would 
arise with a larger sample; they did not perform extensive testing for heteroplasmy throughout 
tissues; the studies did not test germ cells for heteroplasmy or assess the health of subsequent 
generations; and cautioned that using sample tests for heteroplasmy as a proxy for health may 
miss other dysfunction.175 
In vitro studies evaluating the development of embryos appeared to raise similar concerns 
from participants at the MRT Meeting.176  According to Dr. Paula Amato and colleagues, some 
studies demonstrated 50% reduced embryo development following PNT, higher rates of 
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abnormal fertilization, and aberrant chromosomal segregation.177  Despite these findings, Dr. 
Amato and colleagues presume that the development of the remaining embryos signals viability 
and health.178  Participants at MRT Meeting disagreed, and instead suggested the remaining 
embryos that survive may also be affected with developmental shortcomings.179  These findings 
have led Dr. David King of Human Genetics Alert to conclude the embryos that do survive may 
develop subtle latent deficits, and has asserted that presuming the opposite− that embryo survival 
equates to safety and efficacy− seems risky.180 
3. Risks Arising from Assisted Reproductive Technology, Oocyte Manipulation, 
and Epigenetic Impact 
In addition facing unpredictability and uncertainty arising from mitochondrial biology, 
the participants at the MRT Meeting and additional research have examined background risks 
arising from using assisted reproductive technology (“ART”), risks from the process and 
procedures involved with MRT, and epigenetic impact on the health of the child. 
Numerous studies have assessed the impact of “considerable epigenetic changes” on the 
health outcomes of children born through the process of ART.181  According to some figures, 
children born through ART have a 30-40% increased rate of major congenital malformations,182 
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increased risk of autism,183 more childhood illness,184 a higher occurrence of cardiovascular 
conditions,185 and an increased risk of cancer.186 
Researchers have hypothesized a number of reasons for such outcomes, including drugs 
used by the mother during ovarian stimulation;187 that impaired fertility may signal existing 
genetic mutations, in either mtDNA or nDNA, in the mother’s oocytes;188 and the impact of 
damage caused to the embryo arising from physical manipulation and the processes used during 
ART.189  Current research suggests a correlation between the amount of physical manipulation to 
the embryo and level of damage resulting in potentially serious health deficits.190  Physical 
damage may result from temperature shifts;191 reagents used and time the embryo spends in 
culture;192 destruction to cellular architecture;193 and with MRT, potential for viral contamination 
based on a particular virus used during the procedures.194  These factors could result in damage 
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to cellular structure, aneuploidy, or disruption of chromosomal segregation and division.195  
Some of the elements introduced during MRT such as temperature changes, use of 
reagents, and changing the composition of mitochondria through MST or PNT may have an 
epigenetic impact on the embryo and modify the expression of nDNA.196  During discussions in 
both the U.K. and the U.S., participants described a critical window of vulnerability during 
which changes to the embryo will influence long term health outcomes through modifying gene 
expression.197  These epigenetic changes could result in “imprinting or programming of future 
disease in children.”198 
During the closing statements by participants at the MRT Meeting, an overwhelming 
number of speakers voiced concern not only that scientific evidence failed to demonstrate safety 
and efficacy,  but that MRT may never be a viable option based on level of risk involved.199  
Participants reiterated there are less risky alternatives to having children, and the current 
evidence falls “far short” of showing MRT would be potentially safe and effective.200  Germline 
modification by its nature means MRT would pose unprecedented risks to the children born as a 
result.201  MRT would impact every cell in the body, and there are no methodologies currently to 
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ensure the procedure would not inflict novel abnormalities. 202  Based on available research, 
scientists cannot currently predict lifetime safety nor latent effects.203  Such mistakes are both 
inevitable and irreversible, which means MRT could potentially not only create a congenitally 
impaired child, but introduce those deficits into the germline of all subsequent offspring.204  
Indeed, current research suggests disrupting mtDNA through MRT may have the potential to 
result in developmental disorders,205 latent fatalities,206 expedited aging,207 increased risk of 
cancer,208 as well as unknown abnormalities.209  The weight of the evidence unquestionably 
points not merely to insufficient evidence of safety and efficacy, but should raise utmost alarm 
for the severity of potentially imposing novel risks.  These extensive considerations do not 
support the National Academies of Science, Engineering, and Medicine Report’s conclusion that 
conducting clinical trials for MRT is ethically permissible. 
D. NAS Report on the Ethical Permissibility of MRT 
Following the FDA’s MRT Meeting and MRT Brief that cited numerous risks and lack of 
evidence pertaining to safety and efficacy, the FDA requested that the National Academies of 
Science, Engineering and Medicine develop a consensus report reviewing the ethical, social, and 
policy considerations relating to MRT.210  The NAS Report concluded it is ethically permissible 
for the FDA to conduct clinical investigations subject to a set of conditions including: (1) Initial 
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safety is established and risks to all parties directly involved in the proposed clinical 
investigations are minimized; (2) Likelihood of efficacy is established by preclinical research; 
(3) Clinical investigations are limited to women who otherwise are at risk of transmitting a 
serious mtDNA disease; (4) Intrauterine transfer for gestation is initially limited to male embryos 
(but may be extended to females if safe and effective); (5) FDA may consider haplotype 
matching as a means of mitigating risk of incompatibilities between mtDNA and nDNA.211 
 The NAS Report stated its goals are to minimize risks to the future child and ensure 
safety and efficacy of clinical interventions.212  Despite setting forth this goal, the substance of 
the NAS Report discussion focused on prioritizing novel technological interventions as a means 
to advance science and medicine, asserting the FDA should exercise caution but not impose 
absolute limits on technology.213  Echoing the position set forth in British media, the NAS 
Report maintained that opposition to MRT arises out of unfounded fear, poor understanding of 
the science, and an irrational belief that “natural” is necessarily better.214  According to the NAS 
Report, parents take steps daily to improve their children through education and using medicine 
when children are ill, and categorized MRT as another option for parents to choose on behalf of 
their children’s health and well-being.   
However, comparing providing an existing child with a proper education against 
undertaking an unprecedented experiment to create a child with known risks that contravenes 
multiple global legal prohibitions are incommensurate actions.  By refusing any absolute limits, 
the NAS Report necessarily weighs the scale in favor of finding benefit in the sake of pursing 
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research for its own sake even when serious reservations of safety and efficacy exist.  At times, 
the notion of progress requires a prudent pause and adherence to limits where technology would 
pose grave risk of harm to the intended recipient.   
The NAS Report also justified the use of MRT based on longstanding jurisprudence 
respecting parental autonomy and procreative liberty.215  In the history of ART, the desire to bear 
genetically related children has been prized, and parents have traditionally been provided wide 
lenience to pursue their “reproductive projects.”216  However, a number of bioethicists have 
observed this right need not be absolute nor demand all technology available without regard to 
whether the original conception of procreative liberty even encompasses such a right, or how 
exercising that right would impinge upon the rights of the child.217 
In a similar manner as the U.K., the NAS Report employed linguistic creativity, asserting 
that although MRT is germline modification, it is not heritable because initial transfer for 
gestation would be limited to males who would not pass on mtDNA to their children.218  
Throughout the NAS Report the NAS took great care to minimize the role of mtDNA, reassuring 
that MRT does not “edit genes” and “there is no direct modification of mtDNA”219 because MRT 
merely replaces pathogenic mtDNA with unaffected mtDNA.220  Designed to minimize the 
impact of MRT as heritable germline modification, this statement is scientifically inaccurate and 
                                                          
215 Id. at 82-83. 
216 Id. at 82-83, 87; Baylis, supra note 29, at 533; Leon Kass, Life, Liberty, and the Defense of 
Dignity (2002). 
217 Baylis, supra note 29, at 533; Kass, supra note 216, at 163-164.   Kass asserts: “When the 
exercise of a previously innocuous freedom now involves or impinges on troublesome practices 
the original freedom was never intended to encompass the general presumption of liberty needs 
to be reconsidered.”  
218 NAS Report, supra note 13, at 29. 
219 Id. at 6-8. 
220 Id. at 107-108. 
41 
 
perpetuates misunderstanding.  The description minimizing the actual procedure of a nuclear 
genome transfer by describing it as switching mitochondria echoes the misleading descriptions 
provide by the HFEA and the U.K. Department of Health.  Furthermore, all germline 
modifications are heritable because changes to the oocyte or embryo globally impact all the 
resulting cells, impacting the growth and development of the child and the expression of nDNA, 
which is passed on by both males and females.221  This attempt at extricating MRT from the 
category of heritable modifications is likely both a move to slowly introduce the concept of 
germline modification as well as a carefully executed strategy to assert that current limitations 
prohibiting federal funding for heritable germline modifications would not apply to MRT.222 
Finally, the NAS Report addressed international treaties and global prohibitions against 
germline modification.223  According to the NAS Report, the language set forth in the United 
Nations Universal Declaration on the Human Genome and Human Rights declaring that the 
genome constitutes “the heritage of humanity” amounts to “vague and aspirational” language, 
and the NAS is “not persuaded that MRT should be prohibited based on arguments that the 
genome represents the inviolable heritage of humanity.”224  The NAS Report’s blatant disregard 
for conclusive positions set forth by the United Nations along with persuasive nonbinding 
precedent set forth by the Council of Europe entails the very action cautioned by the UNESCO’s 
International Bioethics Committee when it warned of parsing component parts of the genome, 
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renouncing limitations, and permitting market forces to stretch the boundaries of permissible 
endeavors.  Furthermore, the position of UNSECO’s International Bioethics Committee, the 
Council of Europe, and criminal prohibitions on germline modification set forth by numerous 
nations demonstrates the United Nations’ language constitutes an unwavering and unmistakable 
directive rather than “vague and aspirational language.”     
VI. Additional Scientific and Ethical Considerations 
After reviewing the scientific elements pertaining to safety, efficacy, and risks at the 
FDA MRT Meeting and the ethical, social, and policy issues contained in the NAS Report, these 
discussions omitted significant additional considerations.  First, permitting clinical investigation 
of MRT and announcing the ethical acceptability of MRT relies upon expanding the pool of 
oocyte donors.  Second, discussions at the FDA and in the NAS Report accept proponent’s 
medical rationale for MRT for uses such as to treat mitochondrial disease and infertility without 
substantive analysis.  Each of these points warrants further discussion to consider how clinical 
investigation would impact crucial parties involved in the process−potentially a new pool of egg 
donors, and whether available evidence supports the findings that MRT constitutes an effective 
method to treat mitochondrial disease and infertility.  
A. Increasing Oocyte Donation and Risks to Donors 
Although limited literature in the area addresses the impact of permitting MRT on oocyte 
donors and increasing risk in the pool potential oocyte donors, these considerations were not 
mentioned during the FDA MRT Meeting nor in the NAS Report.225  MRT not only poses 
significant risks to the child, but because it relies upon oocyte donation, it would require 
increasing the number of oocyte donors and compound the current ethical debates pertaining to 
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the acceptability of risk and conflicts of interest present in this sector of the fertility industry.226  
Although some scholars reason autonomy and informed consent obviate ethical hesitation, this 
conclusion deserves further investigation.227    
Every year, millions of women donate oocytes and are generally paid $5,000-$20,000 per 
cycle.228  The process of egg donation requires multiple steps, beginning with a medical 
screening questionnaire and blood tests to check for infectious disease.  If the fertility clinic 
selects this egg donor, then the clinic will begin the process of coordinating the donor’s 
hormonal cycle with the intended mother’s by starting a ten to twenty one day cycle of a 
hormone such as Lupron to suppress ovulation followed by a seven to twelve day regimen of 
injections of high doses of follicular stimulating hormones.229  When the donor’s oocytes have 
matured, the fertility clinic administers a final injection of human chorionic gonadotropin.  After 
the injection of human chorionic gonadotropin, the donor undergoes surgery with anesthesia, 
where the physician inserts a needle through her vagina to remove the eggs that were 
produced.230  Unlike a normal monthly cycle that produces one egg, this procedure generally 
produces around ten to twenty eggs or more depending on the amount of fertility drugs the clinic 
uses.231   
The process of egg donation exposes donors to a number of short term physical risks in 
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connection to the fertility drugs used and the surgical process of retrieving the eggs.  Adverse 
effects from the hormone injections may include pain, nausea, hot flashes, mood swings, hair 
loss, depression, bone pain, chronic enlargement of the thyroid, liver dysfunction, and heavy 
bleeding.232  Ironically, evidence also suggests hormone injections of Lupron, a drug to suppress 
ovulation commonly during the process of syncing the donor’s cycle to the mother’s, can lead to 
the donor’s own infertility because it may disrupt long term ovarian function in the donor.233  
Drugs used during this process can also result in ovarian torsion, where the ovaries change 
position from the drug induced stimulation in a manner that blocks blood flow and twists the 
ovary.234  This condition requires medical intervention to remediate and may result in loss of 
ovarian function or surgical removal of the ovary.235  The surgical process of egg retrieval carries 
risks associated with general surgery such as danger of infection, complications from anesthesia, 
and hemorrhage, as well risks related to the process of egg retrieval such as injury to adjacent 
areas like the ureter, bladder, or bowel.236 
Donors may also experience ovarian hyperstimulation syndrome (“OHSS”), which is 
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fluid build-up in the abdomen and chest caused by gonadotropin stimulation of the ovaries.237  
Fluid leads to pressure on the diaphragm that causes difficulty breathing and decreases blood 
volume.  In severe cases, OHSS can lead to kidney damage, blood clotting disorders, stroke, and 
death.238  Estimates suggest the majority of women undergoing egg retrieval experience at least 
mild OHSS.239  Although the fertility industry has stated complications from donation and OHSS 
are rare, such an assertion is not supported by available data.240  Although fertility clinics keep 
statistics on pregnancy outcomes, they generally do not keep records on medical complications 
associated with the process of donating.241  Recent independent research that studied the 
frequency of complications found varying rates of adverse events: approximately thirty percent 
of donors suffered OHSS, and between eleven and thirty percent of donors suffered 
complications so severe they required hospitalization.242   
Despite the American Society for Reproductive Medicine’s claim that there are no long 
term adverse risks of egg donation, this statement inaccurately represents both the known and 
unknown long terms risks associated with being an egg donor.243  There are currently no 
registries tracking either short term or long term donor outcomes, so comprehensive data for all 
donors simply does not exist.244  Despite lack of donor wide registries, numerous studies have 
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explored the link between different drugs used during the donation process and in numerous 
cases found an increased risk for a variety of cancers, including colon, breast, endometrial, 
uterine, ovarian cancer as well as malignant melanoma and non-Hodgkins lymphoma.245  
Donation may also result in long term compromise of the donor’s own fertility, chronic pelvic 
pain and ovarian cysts.246  
Critics of the current donation process have noted deficiencies arising from insufficient 
informed consent and conflicts of interest inherent in the egg donation process.  Despite evidence 
demonstrating these short term and long term risks, donors may not even be aware of these risks 
when deciding to undergo donation.247  One study found twenty percent of donors were not 
aware there were health risks involved, let alone serious complications such as OHSS, loss of her 
own fertility, and increased risk of cancer.248  This discrepancy suggests serious deficiencies in 
the informed consent process.249  Fertility clinics’ metrics of success hinge upon successful 
pregnancies, which also creates an incentive for clinics to increase the dosage of fertility drugs to 
produce more eggs in one cycle.250  Although higher doses of drugs will yield more eggs and 
benefit the clinic, it also places the egg donor at greater risk of adverse health consequences.251   
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Legal scholars assert this creates a system that treats oocyte donors as separate and 
fungible producers of raw materials for a lucrative industry.252  If the fertility industry would 
accurately disclose and assess risks, this would jeopardize donor willingness and undermine the 
supply of raw material upon which fertility clinics rely.253  Discussions that euphemistically refer 
to “cytoplasm donors,”254 and swapping out mitochondria obscures the fact that MRT relies on a 
supply of eggs that entails potentially serious risks to egg donors, of which they may not even be 
aware.  Failing to address where the raw materials for MRT originated and focusing solely on 
risks to the child skews the risk-benefit ratio of this experimental procedure.  Thus, even those 
who believe MRT in potential benefit to the child must also evaluate whether this benefit is 
justified at the expense of placing a pool of women’s health at risk for the “reproductive 
projects” of third parties.255   
B. Evaluating the Medical Rationale of Using MRT to Treat Mitochondrial Disease 
and Infertility 
1. Sources of Mitochondrial Dysfunction  
In addition to the risk profile for MRT, it is crucial to analyze whether MRT would 
effectively and sustainably address causes of mitochondrial dysfunction.  As stated in Section II, 
dysfunction may result from either mtDNA mutations or nDNA mutations.  Eighty percent of 
mitochondrial dysfunction arises from nDNA mutations for which MRT would not address.   
Mitochondrial DNA mutations may either be maternally inherited or arise de novo, as new 
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mutations.  Recent evidence suggests that a variety of environmental factors induce de novo 
mutations.  Mitochondrial dysfunction is not only a cause of rare fatal disease, but also has been 
implicated as a factor in the development of common diseases, such as neurodegenerative 
disease, cancer, diabetes, cardiovascular disease.256  Public health researchers hypothesize that 
the rising rates of chronic and debilitating disease are a product of environmentally mediated 
epigenetic damage to our mitochondria.257  Changes in mitochondrial integrity appear to 
influence a number of diseases, more than the traditionally defined classes of maternally 
inheritance of mtDNA disease and nDNA mitochondrial disease.   
 Mitochondria undergo rapid development called mitochondrial biogenesis during 
embryonic and fetal development, and continue to replicate throughout one’s lifetime.  During 
this critical window of early development, altered maternal mitochondrial function directly 
impacts fetal development.258  If mitochondria are damaged during these early stages, scientists 
believe the mtDNA deficiencies will continue to replicate during the growth of the organism.259  
Mitochondria undergo continual growth and repair throughout the life cycle of the organism, but 
if the cell’s repair mechanisms cannot keep pace with external assaults that induce these changes, 
cumulative damage will eventually manifest phenotypically in a disease state.260   
In the course of one’s life mitochondria are “on the frontline of cellular response to the 
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environment.”261  Recent research demonstrates how environmental factors induce epigenetic 
changes in mitochondrial activity that can also lead to alternation in nDNA.262  A variety of 
environmental agents, including pesticides,263 heavy metals,264 antibiotics,265 pharmaceutical 
drugs,266 environmental toxicants such as dioxin267 and Bisphenol A268 can all exert changes to 
mitochondrial integrity and development.  Over time, exposure to mitochondrial disruptors 
damages the mitochondria and impacts the resulting health of the individual.  As discussed in 
Section II, proper functioning of each cell and the organism as a whole relies on cross-talk 
between mtDNA and nDNA.  Environmentally mediated mtDNA damage undermines 
bidirectional cross-talk and interferes with nDNA repair pathways, which can influence nDNA 
methylation and produce epigenetic changes in the expression of nDNA.269  When accumulations 
of mtDNA damage and nDNA damage reaches a particular threshold, this manifests as common 
diseases.270 
This research suggests that even presuming the initial procedure of MRT could ever be 
safe and effective, it would not address underlying causes of de novo mtDNA mutations nor de 
novo nDNA mutations that phenotypically present as disease.  These findings have several 
implications for the long term safety and efficacy of MRT over the course of the child’s life.  
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First, even if MRT could be safe and effective in principle (a hypothesis that is currently 
unsupported), exposure to mitochondrial disruptors during biogenesis and over the course of the 
child’s life has the potential to undo theoretical mitochondrial correction as damage accumulates.  
Based on scientific concerns related to cross-talk between mtDNA and nDNA, this also raises 
questions of whether disrupting the naturally occurring cross-talk would have negative 
implications for the mitochondria’s evolutionary ability to adapt to the influence of 
mitochondrial disruptors.271  Finally, this area of research demonstrates that rare fatal disease 
arising from mitochondrial dysfunction merely constitutes the tip of the iceberg.  Promoting 
MRT as a viable option distracts from the heavy burden of environmentally mediated mtDNA 
and nDNA damage quietly influencing the rates of common and chronic disease.  Recognizing 
and reducing these exposure levels should constitute the focus of the inquiry, along with 
concurrent low risk interventions such as exercise and dietary measures, which have been shown 
to enhance mitochondrial function. 272 
2. Causes of Infertility 
The FDA MRT Meeting also considered the possibility of clinical trials to explore using 
MRT to treat infertility, and some have suggested treating infertility constitutes the end goal.273 
Though the NAS Report limited its recommendation that the FDA limit applications to treatment 
of mtDNA disease, the FDA is not bound by NAS’s recommendation.  Furthermore, even if the 
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FDA were to approve an investigational new drug application related to MRT, the fertility clinic 
could subsequently use the approved MRT procedure off label for infertility and other purposes.  
Investigating the medical rationale of using MRT to treat infertility raises a similar set of 
findings with research demonstrating that rising rates of impaired fertility are likely due to a 
variety of complex environmental and lifestyle causes including aging, not inherent genetic 
flaws.274   
A portion of infertility stems from aging, and as one gynecologist observed, trying to 
change biology is “incredibly difficult and expensive to alter.”275  Popular media articles and 
scholars have questioned the social messaging behind the cultural phenomenon of delaying 
motherhood, asking why addressing age related reproductive complications and limitations have 
become taboo.276  During the FDA MRT Meeting, participants discussed a number of age related 
biological changes such as diminished ovarian function, risk of aneuploidy, genetic segregation 
errors, and oocyte structural defects.277  If aging increases the risk of aneuploidy or mutations to 
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nDNA contained in maternal oocytes, MRT would not address these concerns because the 
procedure transfers nDNA from the mother to the donor.278  
In addition to age, research suggests lifestyle choices can directly impact both female and 
male fertility outcomes.  Factors such as smoking, alcohol use, diet, and sedentary lifestyle have 
been shown to negatively correlate to fertility outcomes.279  Some promising research suggests 
positive effects of dietary changes and moderate exercise as an avenue to improve fertility.280   
Despite these potential causes, infertility is dramatically rising in the population of young 
adults in their twenties which has led researchers to investigate additional causes.  Research 
implicates a variety of environmental toxicants including pesticides, PCBs, phthalates, parabens, 
and Bisphenol A that are present in our daily environment and act as endocrine disrupting 
chemicals (EDCs) contributing to rising rates of impaired fertility.281  In 2012, the World Health 
Organization and the United Nations Environment Program published a report, “State of the 
Science on Endocrine Disrupting Chemicals” on the impact of EDCs on human reproduction.282  
Currently, there are eight hundred chemicals that are known or suspected to be capable of 
interfering with human reproduction.283  Exposure to EDCs can interfere with hormone 
synthesis, conversion, and signaling, which can impair growth throughout the life cycle and 
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reproductive capability.284    
Scientists describe a period called the critical window of development during gestation 
and early infancy, during which exposure to toxicants can alter normal development and 
manifest in acute or long term health effects.285 During fetal development, the brain and fetal 
tissue undergo rapid development along a specific pathway.286  Any exposure to toxicants during 
this crucial stage could halt or alter the normal course of proper hormone signaling and fetal 
tissue differentiation leading to long lasting and permanent health deficits.287  These deficits may 
manifest through a number of avenues in females including ovarian dysgenesis, premature 
ovarian failure, anovulation, and irreversible morphological abnormalities in the human 
reproductive tract.288  Importantly, an extensive body of research demonstrates both females and 
males are affected by rising rates of infertility.289  In males, the impact of EDCs may result in 
low testosterone, a decrease in semen quality, reduction in sperm, and deficiencies in sperm 
motility, disruption of testicular development, and abnormalities of the male reproductive 
tract.290   
Exposures to EDCs during the critical window and throughout the course of one’s life 
have the potential to exert epigenetic changes not only to the individual’s somatic cells, but also 
to the germ cells.291  This means EDCs are not only changing the individual’s reproductive 
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capacities, but also transmitting altered epigenetic marks to subsequent generations and 
potentially compromising the offspring’s fertility as well.292 
As a whole, this research suggests that the medical rationale of using MRT to treat 
infertility contains numerous flaws.  Even presuming MRT could ever be safe and effective, it 
fails to address impaired fertility that could be prevented through social policy movements that 
encourage reproduction during biologically viable years and lifestyle modifications that support 
fertility potential.  MRT also would not address the various deficiencies in female reproductive 
capacity such as reproductive tract abnormalities or insufficient ovarian reserve.  MRT would 
also not address any of the growing concerns related to male infertility.  Scientific research in 
this area suggests a need to systematically address the underlying factors contributing to 
population level fertility impairment. 
C. Assessing the Potential for Market Expansion 
After deconstructing the medical rationale, proponents’ claims that MRT could treat 
mitochondrial disease and infertility become less compelling.  This raises questions of why 
proponents would aggressively push a highly risky experimental technology.  Developing MRT 
to offer as the newest option in the treatment of infertility holds substantial value for industry 
revenue and commercial expansion, both domestically and as a means to increase the U.S. 
fertility industry’s global market share.293   
Statistics vary, but according to the Centers for Disease Control, approximately twelve 
percent of couples in the U.S. suffer from impaired fecundity, defined as the inability to get 
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pregnant or carry a baby to term.294  The World Health Organization evaluated global rates of 
infertility, finding up to one quarter of couples of childbearing age suffer from infertility.295  In 
the U.S., 62 million women of childbearing age are infertile and 7.4 million women seek fertility 
services during their life.296  These figures translate into a lucrative industry and “sprawling 
commercial enterprise,”297 estimated to be between $3 to 4 billion dollars in the United States, 
with demand growing approximately ten percent annually.298     
Rising rates of impaired fertility combined with the promise of a genetically related child 
have produced a booming market.  Having a genetically related child satisfies a deeply held 
primal desire, but as legal scholar Lisa Ikemoto observed, industry’s focus on emotional stories 
“is compelling because it is real” but it “elides the commercial nature of the practice.”299  
Focusing on the pathos of parental yearning distracts from the consumerism, including how 
potential parents also constitute vulnerable participants in their quest for parenthood.300   
Historian Nathaniel Comfort maintains prioritizing the technological imperative and mastery of 
science over nature categorizes emerging technology as a “humane” option for medical suffering 
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offered with a “veneer of benevolence.”301  Yet Comfort notes viewing new technology in this 
manner fails to situate it within the broader context of a free market system that brutally 
capitalizes on the newest technology, at times at the expense of those who seek it. 302 
We must be cautious of the commercial market driving the adoption of new technology 
such as MRT, because the market prioritizes expansion and profit increase as a primary goal, 
which creates a conflict of interest with parents, children, and egg donors in MRT.303  Minimal 
regulation combined with a high demand for services means the ART industry has little incentive 
to collect and analyze important data related to risk, outcomes, and efficacy beyond basic 
statistics related to viable pregnancies.304  This shifts external costs related to latent risks and 
long term harm onto parents, donors, and children.305  Unlike other classes of physicians who are 
passive providers, the fertility industry constitutes influential stakeholders where the physicians 
themselves consistently push for implementing risky experimental techniques as a means of 
expanding and increasing their market position.306  If the fertility industry offers MRT in the U.S. 
pursuant to an FDA submission, this provides the imprimatur of safety and efficacy, even though 
the procedure may indeed pose long term and latent risks to the child and the child’s offspring.  
Alternatively, the fertility industry may opt to forgo pursuing an investigational new drug 
submission but continue to offer MRT as a service the clinic coordinates to perform in another 
country.  
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Permitting, or even insisting, that individuals have access to risky experimental 
reproductive techniques has the potential to increase reproductive tourism into the U.S. as 
destination point for MRT.307  Legal scholars have described how the convergence of 
globalization and the fertility market has resulted in potential parents crossing borders, seeking a 
country that permits them to fulfill their parental desire.308  Restrictions in some countries have 
led to strategic jurisdictional forum shopping, precisely illustrated by the example of Dr. Zhang.  
Potential parents willing to travel great lengths may seek out niche markets that offer what 
appear to be the newest and best products and services in an attempt to achieve a pregnancy, or 
even elect to use MRT as an energetic corrective preventive practice against aging, obesity, and 
common disease in the future child.309   
VII. Recommendations 
Promoting MRT as a method to assist suffering potential parents fails to acknowledge the 
substantial weight assigned to scientific innovation and commercial profit incentives driving the 
scientific and fertility industry.  This framing not only lacks transparency, but appears ethically 
troublesome based on the concerted effort during the policymaking process to dismiss the risks 
involved in MRT and modifying the human germline.310  As one bioethicist questioned, “Who is 
applying the brakes?  Private entities are profit driven, which is the last question we should 
consider when altering the human race.”311  The U.S. appears poised to not only to accept 
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inflated promises of MRT, but to do so through a policymaking process that provided the 
appearance of deliberation while issuing conclusions against the weight of the scientific 
evidence.  This sets a dangerous precedent, where implicit prioritization of scientific exploration 
and commercial interests directs governance outcomes in a manner that implicitly subverts 
considering risks to human health.  In this instance, the weight of the scientific evidence not only 
suggests creating children through MRT may not be safe or effective, but that the procedure may 
impose new health deficits such as an increased risk of developmental disorders, latent fatalities, 
expedited aging, cancer, and congenital abnormalities.    
Although some appear resigned to the power of these “baby markets,”312 I assert we have 
a duty to use federal regulation as a mechanism to insulate parents, donors, and children from 
substantial risks inherent in MRT as well as new technological iterations that promise to correct 
genomic flaws by prohibiting modification of the human germline.  Commercial and scientific 
interests have painted a false double bind: regulation that entails callous prohibitions stifling 
innovation to that could otherwise help parents have healthy children, or an unhampered free 
market wherein the fertility industry can produce miracles.  Confined to the impossible choices 
in this narrative blocks us from considering the crucial questions raised here: such as whether the 
scientific risks mirror the policymaking outcome; why the discussion glosses over risks to oocyte 
donors; how the science fails to support the medical rationale for MRT; and the 
inappropriateness of permitting commercial motivations to drive the adoption of MRT. 
Rather than prioritizing scientific ingenuity and economic profit, the U.S. and other 
nations have a duty to enact measures that discourage risky experimentation on future 
generations through MRT and other forms of germline modifications.  I affirm the proposition 
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that future generations have a right to an “untampered genome.” 313  I further assert that each 
individual has a human right to be born without intentional germline interventions, and we have 
an ethical duty to investigate and mitigate sources that threaten the integrity of our health.  This 
duty encompasses a diligence to properly situate and analyze whether proponents’ medical 
rationale matches available evidence or constitutes a strategic appeal to our pathos.  This stance 
against MRT and other germline interventions coincides with the scientific opinion that our 
inability to accurately predict the outcomes of potential interventions means germline 
modifications including MRT should not be permitted.314  Germline interventions pose 
significant risk and carry the threat of unintended consequences that are both irreversible and 
permanent.315  The consensus against germline modifications set forth by UNESCO’s 
International Bioethics Committee, the Council of Europe, and numerous other nations should 
remain intact to protect the health of future generations.   
New regulations enacted in other nations should affirm this prohibition through 
unambiguous legislative measures.  At the federal level, nations should not rely on funding 
restrictions, but enact criminal prohibitions for human germline modification of human embryos.  
These statutes should prohibit the creation of embryos with germline modifications for 
implantation and include additional mechanisms to dissuade implantation.  Nations should 
recognize the transnational nature of this research and the convergence of forum shopping and 
reproductive tourism.  As a mechanism to deter avenues of legal circumvention through 
reproductive tourism, nations should include prohibitions on recruitment of potential patients for 
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impermissible procedures to create embryos with germline modifications, whether through MRT 
or another procedure, performed in another nation.  These laws could also include a prohibition 
on the import and export of unauthorized human embryos for implantation.  The statute should 
specify explicit criminal penalties that would reflect the gravity for potential harm of 
experimenting on future generations. 
VIII. Conclusion 
UNESCO’s International Bioethics Committee cautioned against a number of elements 
that appear to be driving the shift in U.S. policy to permit MRT.  Proponents of MRT employed 
reductionist explanations and simplified mitochondria’s function, belying its complex 
evolutionary role, its impact on nDNA expression, and dismissed extensive doubts in the 
scientific community pertaining to safety and efficacy.  Media articles in the U.S. praised Dr. 
Zhang for traveling to Mexico to perform MRT as a “therapy” to “save lives” and circumvent 
FDA jurisdiction.  These actions directly contravened the International Bioethics Committee’s 
directives for the media to avoid sensationalist journalism and renounce regulatory 
circumvention.  During FDA meetings to discuss MRT to treat mitochondrial disease or 
infertility, many participants concluded the evidence falls “far short” of showing MRT could be 
safe and effective and asserted MRT could induce new permanent and irreversible health deficits 
in the child, in addition to existing risks arising from ART.  MRT would also require increasing 
the pool of oocyte donors, which imposes potentially serious health consequences such as OHSS, 
impaired fertility, and increased risk of cancer on a class of women in exchange for payment to 
satisfy the reproductive projects of third parties.  These risks pose significant burdens on both 
future children and oocyte donors.  Furthermore, analysis of the medical rationale reveals MRT 
would not address a substantial portion of conditions related to mitochondrial dysfunction and 
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the complex factors influencing rising rates of infertility.  The NAS Report’s conclusion that 
conducting clinical investigations for MRT is ethically permissible is unsupported by the weight 
of the evidence and appears to prioritize the technological imperative and its potential to grow 
the U.S. global market share in novel fertility industry options. 
